{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:48:53Z","timestamp":1793832533692,"version":"4.6.1"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41584-024-01158-w","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:03:01Z","timestamp":1727190181000},"page":"699-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Lupus nephritis-related chronic kidney disease"],"prefix":"10.1038","volume":"20","author":[{"given":"Julia","family":"Lichtnekert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-2956","authenticated-orcid":false,"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"1158_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"H-J Anders","year":"2020","unstructured":"Anders, H.-J. et al. Lupus nephritis. Nat. Rev. Dis. Prim. 6, 7 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1158_CR2","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali, C. et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc. Res. 119, 2017\u20132032 (2023).","journal-title":"Cardiovasc. Res."},{"key":"1158_CR3","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bph.15734","volume":"179","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal, J., Jaisser, F. & Anders, H.-J. The mineralocorticoid receptor in chronic kidney disease. Br. J. Pharmacol. 179, 3152\u20133164 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"1158_CR4","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408 (2011).","journal-title":"J. Clin. Invest."},{"key":"1158_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","volume":"38","author":"T Speer","year":"2013","unstructured":"Speer, T. et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38, 754\u2013768 (2013).","journal-title":"Immunity"},{"key":"1158_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski, J., Floege, J., Fliser, D., B\u00f6hm, M. & Marx, N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143, 1157\u20131172 (2021).","journal-title":"Circulation"},{"key":"1158_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.2215\/CJN.12691117","volume":"13","author":"A Jovanovich","year":"2018","unstructured":"Jovanovich, A., Isakova, T. & Stubbs, J. Microbiome and cardiovascular disease in CKD. Clin. J. Am. Soc. Nephrol. 13, 1598\u20131604 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1158_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0022-2143(98)90170-6","volume":"132","author":"RC Williams","year":"1998","unstructured":"Williams, R. C., Malone, C. C., Miller, R. T. & Silvestris, F. Urinary loss of immunoglobulin G anti-F(ab\u2032)2 and anti-DNA antibody in systemic lupus erythematosus nephritis. J. Lab. Clin. Med. 132, 210\u2013222 (1998).","journal-title":"J. Lab. Clin. Med."},{"key":"1158_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1681\/ASN.2021091257","volume":"33","author":"S Steiger","year":"2022","unstructured":"Steiger, S., Rossaint, J., Zarbock, A. & Anders, H.-J. Secondary immunodeficiency related to kidney disease (SIDKD) \u2014 definition, unmet need, and mechanisms. J. Am. Soc. Nephrol. 33, 259\u2013278 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296\u20131305 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/ard-2023-224762 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1158_CR12","doi-asserted-by":"publisher","first-page":"ii50","DOI":"10.1093\/ndt\/gfad069","volume":"38","author":"H-J Anders","year":"2023","unstructured":"Anders, H.-J., Fernandez-Juarez, G. M., Vaglio, A., Romagnani, P. & Floege, J. CKD therapy to improve outcomes of immune-mediated glomerular diseases. Nephrol. Dial. Transpl. 38, ii50\u2013ii57 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfac304","volume":"38","author":"AA Perez-Arias","year":"2023","unstructured":"Perez-Arias, A. A. et al. The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Nephrol. Dial. Transpl. 38, 884\u2013893 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR14","doi-asserted-by":"crossref","unstructured":"Summary of recommendation statements. Kidney Int. Suppl. 3, 5\u201314 (2013).","DOI":"10.1038\/kisup.2012.77"},{"key":"1158_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000932","volume":"10","author":"A Malvar","year":"2023","unstructured":"Malvar, A. et al. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients. Lupus Sci. Med. 10, e000932 (2023).","journal-title":"Lupus Sci. Med."},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1177\/09612033231204070","volume":"32","author":"A Malvar","year":"2023","unstructured":"Malvar, A., Alberton, V., Recalde, C. & Heguilen, R. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with mycophenolate associated with belimumab or mycophenolate plus standard of care therapy. A \u2018post-hoc\u2019 analysis of participants in the BLISS-LN and open label extension study belonging to a single center. Lupus 32, 1394\u20131401 (2023).","journal-title":"Lupus"},{"key":"1158_CR17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1681\/ASN.2016070806","volume":"28","author":"JS Tangren","year":"2017","unstructured":"Tangren, J. S. et al. Pregnancy outcomes after clinical recovery from AKI. J. Am. Soc. Nephrol. 28, 1566\u20131574 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaut.2016.06.012","volume":"74","author":"G Moroni","year":"2016","unstructured":"Moroni, G. et al. Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J. Autoimmun. 74, 194\u2013200 (2016).","journal-title":"J. Autoimmun."},{"key":"1158_CR19","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2, 16039 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1158_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/1573397115666190626111847","volume":"16","author":"AY Ali","year":"2020","unstructured":"Ali, A. Y., Abdelaziz, T. S. & Behiry, M. E. The prevalence and causes of non-adherence to immunosuppressive medications in patients with lupus nephritis flares. Curr. Rheumatol. Rev. 16, 245\u2013248 (2020).","journal-title":"Curr. Rheumatol. Rev."},{"key":"1158_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/acr.24155","volume":"73","author":"S Garg","year":"2021","unstructured":"Garg, S., Unnithan, R., Hansen, K. E., Costedoat-Chalumeau, N. & Bartels, C. M. Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res. 73, 707\u2013716 (2021).","journal-title":"Arthritis Care Res."},{"key":"1158_CR22","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677\u20132686 (2012).","journal-title":"Arthritis Rheum."},{"key":"1158_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5935\/0101-2800.20130043","volume":"35","author":"ARP Sabino","year":"2013","unstructured":"Sabino, A. R. P. et al. Detection of podocyturia in patients with lupus nephritis. J. Bras. Nefrol. 35, 252\u2013258 (2013).","journal-title":"J. Bras. Nefrol."},{"key":"1158_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","volume":"6","author":"JB Kopp","year":"2020","unstructured":"Kopp, J. B. et al. Podocytopathies. Nat. Rev. Dis. Prim. 6, 68 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1158_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41581-021-00510-7","volume":"18","author":"VA Luyckx","year":"2022","unstructured":"Luyckx, V. A. et al. Nephron overload as a therapeutic target to maximize kidney lifespan. Nat. Rev. Nephrol. 18, 171\u2013183 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR26","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878\u20131890 (2023).","journal-title":"Lancet"},{"key":"1158_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/1744666X.2018.1538789","volume":"14","author":"V Ocampo-Piraquive","year":"2018","unstructured":"Ocampo-Piraquive, V., Nieto-Aristiz\u00e1bal, I., Ca\u00f1as, C. A. & Tob\u00f3n, G. J. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert. Rev. Clin. Immunol. 14, 1043\u20131053 (2018).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1158_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ckj\/sfx063","volume":"11","author":"CL Teh","year":"2018","unstructured":"Teh, C. L. et al. Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience. Clin. Kidney J. 11, 56\u201361 (2018).","journal-title":"Clin. Kidney J."},{"key":"1158_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00897-3","author":"T Inoue","year":"2023","unstructured":"Inoue, T. & Kurosaki, T. Memory B cells. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-023-00897-3 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cells9030531","volume":"9","author":"I Raphael","year":"2020","unstructured":"Raphael, I., Joern, R. R. & Forsthuber, T. G. Memory CD4+ T cells in immunity and autoimmune diseases. Cells 9, 531 (2020).","journal-title":"Cells"},{"key":"1158_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","volume":"43","author":"JL Halliley","year":"2015","unstructured":"Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow. Immunity 43, 132\u2013145 (2015).","journal-title":"Immunity"},{"key":"1158_CR33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41590-022-01345-5","volume":"23","author":"X Liu","year":"2022","unstructured":"Liu, X., Yao, J., Zhao, Y., Wang, J. & Qi, H. Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota. Nat. Immunol. 23, 1564\u20131576 (2022).","journal-title":"Nat. Immunol."},{"key":"1158_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36\u201346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee, D. S. W., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug. Discov. 20, 179\u2013199 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1158_CR36","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1158_CR37","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1158_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1158_CR40","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070\u20132080 (2021).","journal-title":"Lancet"},{"key":"1158_CR41","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149\u20131155 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/0961203313518625","volume":"23","author":"AS Alvarado","year":"2014","unstructured":"Alvarado, A. S. et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 23, 840\u2013847 (2014).","journal-title":"Lupus"},{"key":"1158_CR43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa, M. et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 94, 788\u2013794 (2018).","journal-title":"Kidney Int."},{"key":"1158_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey, A. S. et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84\u2013104 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1158_CR45","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","volume":"34","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Change in albuminuria and GFR slope as joint surrogate end points for kidney failure: implications for phase 2 clinical trials in CKD. J. Am. Soc. Nephrol. 34, 955\u2013968 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2215\/CJN.11070821","volume":"17","author":"A Armenta","year":"2022","unstructured":"Armenta, A., Madero, M. & Rodriguez-Iturbe, B. Functional reserve of the kidney. Clin. J. Am. Soc. Nephrol. 17, 458\u2013466 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1158_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku, E., Lee, B. J., Wei, J. & Weir, M. R. Hypertension in CKD: core curriculum 2019. Am. J. Kidney Dis. 74, 120\u2013131 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"1158_CR48","doi-asserted-by":"publisher","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","volume":"3","author":"P Romagnani","year":"2017","unstructured":"Romagnani, P. et al. Chronic kidney disease. Nat. Rev. Dis. Prim. 3, 17088 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1158_CR49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2215\/CJN.01880216","volume":"11","author":"AS Bomback","year":"2016","unstructured":"Bomback, A. S. & Markowitz, G. S. Lupus podocytopathy: a distinct entity. Clin. J. Am. Soc. Nephrol. 11, 547\u2013548 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1158_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1681\/ASN.2021111447","volume":"34","author":"X Yuan","year":"2023","unstructured":"Yuan, X. et al. Genetic variants of the COL4A3, COL4A4, and COL4A5 genes contribute to thinned glomerular basement membrane lesions in sporadic IgA nephropathy patients. J. Am. Soc. Nephrol. 34, 132\u2013144 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR51","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2021.04.017","volume":"78","author":"J Savige","year":"2021","unstructured":"Savige, J. & Harraka, P. Pathogenic variants in the genes affected in Alport syndrome (COL4A3\u2013COL4A5) and their association with other kidney conditions: a review. Am. J. Kidney Dis. 78, 857\u2013864 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1158_CR52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/ndt\/gfab351","volume":"38","author":"H-J Anders","year":"2023","unstructured":"Anders, H.-J. et al. The management of lupus nephritis as proposed by EULAR\/ERA 2019 versus KDIGO 2021. Nephrol. Dial. Transpl. 38, 551\u2013561 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR53","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ndt\/gfw234","volume":"31","author":"P Romagnani","year":"2016","unstructured":"Romagnani, P. et al. Next generation sequencing and functional analysis of patient urine renal progenitor-derived podocytes to unravel the diagnosis underlying refractory lupus nephritis. Nephrol. Dial. Transpl. 31, 1541\u20131545 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrneph.2017.181","volume":"14","author":"JJ Carrero","year":"2018","unstructured":"Carrero, J. J., Hecking, M., Chesnaye, N. C. & Jager, K. J. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat. Rev. Nephrol. 14, 151\u2013164 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR55","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00296-009-1151-9","volume":"30","author":"JF de Carvalho","year":"2010","unstructured":"de Carvalho, J. F., do Nascimento, A. P., Testagrossa, L. A., Barros, R. T. & Bonf\u00e1, E. Male gender results in more severe lupus nephritis. Rheumatol. Int. 30, 1311\u20131315 (2010).","journal-title":"Rheumatol. Int."},{"key":"1158_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrneph.2017.189","volume":"14","author":"KMM Colafella","year":"2018","unstructured":"Colafella, K. M. M. & Denton, K. M. Sex-specific differences in hypertension and associated cardiovascular disease. Nat. Rev. Nephrol. 14, 185\u2013201 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(13)60311-6","volume":"382","author":"VA Luyckx","year":"2013","unstructured":"Luyckx, V. A. et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 382, 273\u2013283 (2013).","journal-title":"Lancet"},{"key":"1158_CR58","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0140-6736(17)30576-7","volume":"390","author":"VA Luyckx","year":"2017","unstructured":"Luyckx, V. A. et al. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet 390, 424\u2013428 (2017).","journal-title":"Lancet"},{"key":"1158_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1056\/NEJMoa020549","volume":"348","author":"G Keller","year":"2003","unstructured":"Keller, G., Zimmer, G., Mall, G., Ritz, E. & Amann, K. Nephron number in patients with primary hypertension. N. Engl. J. Med. 348, 101\u2013108 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR60","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies GroupSGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium.","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group & SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788\u20131801 (2022).","journal-title":"Lancet"},{"key":"1158_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","volume":"39","author":"F Caravaca-Font\u00e1n","year":"2023","unstructured":"Caravaca-Font\u00e1n, F. et al. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrol. Dial. Transpl. 39, 328\u2013340 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR62","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/ard-2023-224242","volume":"82","author":"X Zhao","year":"2023","unstructured":"Zhao, X. et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann. Rheum. Dis. 82, 1328\u20131340 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1158_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225248","author":"MJ Soler","year":"2024","unstructured":"Soler, M. J., Jacobs Cach\u00e1, C. & Anders, H.-J. Correspondence on: \u2018SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy\u2019 by Zhao et al. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/ard-2023-225248 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1158_CR64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","volume":"7","author":"JA Kellum","year":"2021","unstructured":"Kellum, J. A. et al. Acute kidney injury. Nat. Rev. Dis. Prim. 7, 52 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1158_CR65","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41581-018-0054-y","volume":"14","author":"N Perico","year":"2018","unstructured":"Perico, N., Askenazi, D., Cortinovis, M. & Remuzzi, G. Maternal and environmental risk factors for neonatal AKI and its long-term consequences. Nat. Rev. Nephrol. 14, 688\u2013703 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000349963","volume":"182","author":"PA McCullough","year":"2013","unstructured":"McCullough, P. A. et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth acute dialysis quality initiative consensus conference. Contrib. Nephrol. 182, 13\u201329 (2013).","journal-title":"Contrib. Nephrol."},{"key":"1158_CR67","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","volume":"376","author":"A Denic","year":"2017","unstructured":"Denic, A. et al. Single-nephron glomerular filtration rate in healthy adults. N. Engl. J. Med. 376, 2349\u20132357 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR68","doi-asserted-by":"crossref","unstructured":"Herold, J. M. et al. Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes. Kidney Int. S0085-S2538(24)00528\u20133 (2024).","DOI":"10.1016\/j.kint.2024.06.024"},{"key":"1158_CR69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1681\/ASN.2016020154","volume":"28","author":"A Denic","year":"2017","unstructured":"Denic, A. et al. The substantial loss of nephrons in healthy human kidneys with aging. J. Am. Soc. Nephrol. 28, 313\u2013320 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR70","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1681\/ASN.2017121305","volume":"29","author":"A Denic","year":"2018","unstructured":"Denic, A. et al. Clinical and pathology findings associate consistently with larger glomerular volume. J. Am. Soc. Nephrol. 29, 1960\u20131969 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR71","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.semnephrol.2021.06.010","volume":"41","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Obesity management and chronic kidney disease. Semin. Nephrol. 41, 392\u2013402 (2021).","journal-title":"Semin. Nephrol."},{"key":"1158_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR73","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon, V. & Thomson, S. C. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat. Rev. Nephrol. 16, 317\u2013336 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR74","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1056\/NEJMcibr1608564","volume":"375","author":"H-J Anders","year":"2016","unstructured":"Anders, H.-J., Davis, J. M. & Thurau, K. Nephron protection in diabetic kidney disease. N. Engl. J. Med. 375, 2096\u20132098 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR75","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/acr.25091","volume":"75","author":"RB Hansen","year":"2023","unstructured":"Hansen, R. B., Falasinnu, T., Faurschou, M., Jacobsen, S. & Simard, J. F. Risk of end-stage renal disease in patients with systemic lupus erythematosus and diabetes mellitus: a Danish nationwide cohort study. Arthritis Care Res. 75, 1871\u20131877 (2023).","journal-title":"Arthritis Care Res."},{"key":"1158_CR76","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/ckj\/sfaa162","volume":"13","author":"S Carriazo","year":"2020","unstructured":"Carriazo, S., Vanessa Perez-Gomez, M. & Ortiz, A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. Clin. Kidney J. 13, 504\u2013509 (2020).","journal-title":"Clin. Kidney J."},{"key":"1158_CR77","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1152\/physrev.00042.2012","volume":"95","author":"M Carlstr\u00f6m","year":"2015","unstructured":"Carlstr\u00f6m, M., Wilcox, C. S. & Arendshorst, W. J. Renal autoregulation in health and disease. Physiol. Rev. 95, 405\u2013511 (2015).","journal-title":"Physiol. Rev."},{"key":"1158_CR78","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","volume":"132","author":"M Burnier","year":"2023","unstructured":"Burnier, M. & Damianaki, A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ. Res. 132, 1050\u20131063 (2023).","journal-title":"Circ. Res."},{"key":"1158_CR79","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/ndt\/gfad118","volume":"38","author":"PI Georgianos","year":"2023","unstructured":"Georgianos, P. I. & Agarwal, R. Hypertension in chronic kidney disease-treatment standard 2023. Nephrol. Dial. Transpl. 38, 2694\u20132703 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR80","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semnephrol.2010.10.002","volume":"31","author":"T Cornelis","year":"2011","unstructured":"Cornelis, T., Odutayo, A., Keunen, J. & Hladunewich, M. The kidney in normal pregnancy and preeclampsia. Semin. Nephrol. 31, 4\u201314 (2011).","journal-title":"Semin. Nephrol."},{"key":"1158_CR81","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1177\/0961203319832097","volume":"28","author":"G Normand","year":"2019","unstructured":"Normand, G. et al. Not only disease activity but also chronic hypertension and overweight are determinants of pregnancy outcomes in patients with systemic lupus erythematosus. Lupus 28, 529\u2013537 (2019).","journal-title":"Lupus"},{"key":"1158_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1753495X18784081","volume":"12","author":"SE Steele","year":"2019","unstructured":"Steele, S. E., Terry, J. E., Page, L. M. & Girling, J. C. Pregnancy in women known to be living with a single kidney. Obstet. Med. 12, 22\u201326 (2019).","journal-title":"Obstet. Med."},{"key":"1158_CR83","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.kint.2017.04.038","volume":"92","author":"A Koratala","year":"2017","unstructured":"Koratala, A. & Kazory, A. Renal functional reserve and pregnancy outcomes. Kidney Int. 92, 768 (2017).","journal-title":"Kidney Int."},{"key":"1158_CR84","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semnephrol.2017.05.006","volume":"37","author":"L Lightstone","year":"2017","unstructured":"Lightstone, L. & Hladunewich, M. A. Lupus nephritis and pregnancy: concerns and management. Semin. Nephrol. 37, 347\u2013353 (2017).","journal-title":"Semin. Nephrol."},{"key":"1158_CR85","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.ekir.2023.04.030","volume":"8","author":"A Verma","year":"2023","unstructured":"Verma, A. & Popa, C. The interplay between dietary sodium intake and proteinuria in CKD. Kidney Int. Rep. 8, 1133\u20131136 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1158_CR86","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.kint.2017.02.032","volume":"91","author":"W Kriz","year":"2017","unstructured":"Kriz, W. & Lemley, K. V. Potential relevance of shear stress for slit diaphragm and podocyte function. Kidney Int. 91, 1283\u20131286 (2017).","journal-title":"Kidney Int."},{"key":"1158_CR87","doi-asserted-by":"publisher","first-page":"151407","DOI":"10.1016\/j.semnephrol.2023.151407","volume":"43","author":"R Elsurer Afsar","year":"2023","unstructured":"Elsurer Afsar, R., Afsar, B. & Ikizler, T. A. Sodium management in kidney disease: old stories, new tricks. Semin. Nephrol. 43, 151407 (2023).","journal-title":"Semin. Nephrol."},{"key":"1158_CR88","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrneph.2012.281","volume":"9","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink, H. J., de Borst, M. H., Bakker, S. J. L. & Navis, G. J. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nat. Rev. Nephrol. 9, 112\u2013121 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR89","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1681\/ASN.2020010028","volume":"31","author":"G-J Ko","year":"2020","unstructured":"Ko, G.-J., Rhee, C. M., Kalantar-Zadeh, K. & Joshi, S. The effects of high-protein diets on kidney health and longevity. J. Am. Soc. Nephrol. 31, 1667\u20131679 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR90","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"1158_CR91","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ntr\/ntaa071","volume":"23","author":"S Lee","year":"2021","unstructured":"Lee, S. et al. Smoking, smoking cessation, and progression of chronic kidney disease: results from KNOW-CKD Study. Nicotine Tob. Res. 23, 92\u201398 (2021).","journal-title":"Nicotine Tob. Res."},{"key":"1158_CR92","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","volume":"26","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert, P., Cheungpasitporn, W., Crowson, C. S. & Matteson, E. L. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur. J. Intern. Med. 26, 285\u2013291 (2015).","journal-title":"Eur. J. Intern. Med."},{"key":"1158_CR93","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 176, 238\u2013246 (2016).","journal-title":"JAMA Intern. Med."},{"key":"1158_CR94","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2215\/CJN.18501120","volume":"16","author":"EYF Wan","year":"2021","unstructured":"Wan, E. Y. F. et al. Comparative risks of nonsteroidal anti-inflammatory drugs on CKD. Clin. J. Am. Soc. Nephrol. 16, 898\u2013907 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1158_CR95","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin, B. H. et al. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 105, S1\u2013S69 (2024).","journal-title":"Kidney Int."},{"key":"1158_CR96","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3390\/cells12202440","volume":"12","author":"A Kale","year":"2023","unstructured":"Kale, A., Shelke, V., Lei, Y., Gaikwad, A. B. & Anders, H.-J. Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis. Cells 12, 2440 (2023).","journal-title":"Cells"},{"key":"1158_CR97","doi-asserted-by":"publisher","unstructured":"Van Schaik, M. et al. Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfae113 (2024).","DOI":"10.1093\/ndt\/gfae113"},{"key":"1158_CR98","unstructured":"Saxena, A., et al. Long-term use of voclosporin in patients with class V lupus nephritis: results from the AURORA 2 continuation study. Abstract number 0355, ACR convergence 2022. Arthritis Rheumatol 74 (2022)."},{"key":"1158_CR99","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis, A. et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713\u2013723 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1158_CR100","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","volume":"18","author":"M Cortinovis","year":"2022","unstructured":"Cortinovis, M., Perico, N., Ruggenenti, P., Remuzzi, A. & Remuzzi, G. Glomerular hyperfiltration. Nat. Rev. Nephrol. 18, 435\u2013451 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1158_CR101","doi-asserted-by":"publisher","first-page":"S819","DOI":"10.1016\/j.ajog.2020.08.108","volume":"226","author":"M Fishel Bartal","year":"2022","unstructured":"Fishel Bartal, M., Lindheimer, M. D. & Sibai, B. M. Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance. Am. J. Obstet. Gynecol. 226, S819\u2013S834 (2022).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1158_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0961203315595130","volume":"25","author":"HS Koo","year":"2016","unstructured":"Koo, H. S., Kim, S. & Chin, H. J. Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis. Lupus 25, 3\u201311 (2016).","journal-title":"Lupus"},{"key":"1158_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000684","volume":"9","author":"E Weeding","year":"2022","unstructured":"Weeding, E., Fava, A., Magder, L., Goldman, D. & Petri, M. One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria. Lupus Sci. Med. 9, e000684 (2022).","journal-title":"Lupus Sci. Med."},{"key":"1158_CR104","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/ndt\/gfaa329","volume":"37","author":"H-J Anders","year":"2022","unstructured":"Anders, H.-J., Peired, A. J. & Romagnani, P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, \u2018diabetic nephropathy\u2019, IgA nephropathy and podocytopathies with FSGS lesions. Nephrol. Dial. Transpl. 37, 1609\u20131615 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1158_CR105","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1177\/0961203318809883","volume":"27","author":"M Castro","year":"2018","unstructured":"Castro, M., Ugolini-Lopes, M., Borba, E. F., Bonf\u00e1, E. & Seguro, L. P. C. Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. Lupus 27, 2215\u20132219 (2018).","journal-title":"Lupus"},{"key":"1158_CR106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","volume":"97","author":"A Malvar","year":"2020","unstructured":"Malvar, A. et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int. 97, 156\u2013162 (2020).","journal-title":"Kidney Int."},{"key":"1158_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000689","volume":"9","author":"M Gatto","year":"2022","unstructured":"Gatto, M. et al. Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis. Lupus Sci. Med. 9, e000689 (2022).","journal-title":"Lupus Sci. Med."},{"key":"1158_CR108","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.21037\/atm.2018.09.47","volume":"6","author":"H-J Anders","year":"2018","unstructured":"Anders, H.-J. Re-biopsy in lupus nephritis. Ann. Transl. Med. 6, S41 (2018).","journal-title":"Ann. Transl. Med."},{"key":"1158_CR109","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/art.30345","volume":"63","author":"S Ardoin","year":"2011","unstructured":"Ardoin, S. et al. An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis. Arthritis Rheum. 63, 2031\u20132037 (2011).","journal-title":"Arthritis Rheum."},{"key":"1158_CR110","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. J. Am. Med. Assoc. 327, 464\u2013477 (2022).","journal-title":"J. Am. Med. Assoc."},{"key":"1158_CR111","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"1158_CR112","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902\u2013914 (2019).","journal-title":"Nat. Immunol."},{"key":"1158_CR113","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/jcm10040626","volume":"10","author":"NL Li","year":"2021","unstructured":"Li, N. L., Birmingham, D. J. & Rovin, B. H. Expanding the role of complement therapies: the case for lupus nephritis. J. Clin. Med. 10, 626 (2021).","journal-title":"J. Clin. Med."},{"key":"1158_CR114","doi-asserted-by":"publisher","first-page":"152263","DOI":"10.1016\/j.semarthrit.2023.152263","volume":"63","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Urine proteomics link complement activation with interstitial fibrosis\/tubular atrophy in lupus nephritis patients. Semin. Arthritis Rheum. 63, 152263 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1158_CR115","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3109\/0886022X.2016.1150099","volume":"38","author":"JB Mansur","year":"2016","unstructured":"Mansur, J. B., Sabino, A. R. P., Nishida, S. K. & Kirsztajn, G. M. Is there a role for urinary podocyte excretion assessment in lupus nephritis? Ren. Fail. 38, 643\u2013647 (2016).","journal-title":"Ren. Fail."},{"key":"1158_CR116","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215\u20131226 (2012).","journal-title":"Arthritis Rheum."},{"key":"1158_CR117","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"1158_CR118","doi-asserted-by":"publisher","unstructured":"Heerspink, H. J. L. et al. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfae132 (2024).","DOI":"10.1093\/ndt\/gfae132"},{"key":"1158_CR119","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30, 2058\u20132066 (2024).","journal-title":"Nat. Med."},{"key":"1158_CR120","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR121","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402, 2077\u20132090 (2023).","journal-title":"Lancet"},{"key":"1158_CR122","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"1158_CR123","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000436","author":"JD Smeijer","year":"2024","unstructured":"Smeijer, J. D. et al. Effects of zibotentan alone and in combination with dapagliflozin on fluid retention in patients with CKD. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000000000436 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1158_CR124","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou, M. G., Dasgupta, A. & Ward, M. M. Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 68, 1432\u20131441 (2016).","journal-title":"Arthritis Rheumatol."}],"updated-by":[{"DOI":"10.1038\/s41584-024-01203-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01158-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01158-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01158-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T19:03:24Z","timestamp":1733771004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01158-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":124,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01158-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41584-024-01203-8","asserted-by":"object"}]},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"14 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41584-024-01203-8","URL":"https:\/\/doi.org\/10.1038\/s41584-024-01203-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.-J.A. has received consultancy and lecture fees from Otsuka, GSK, AstraZeneca, Bayer, Boehringer Ingelheim, Roche, Novartis and SOBI.\u00a0J.L. declares no\u00a0competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}